Status:
COMPLETED
A Trial of Vitamin B12 in Septic Shock
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will randomize 20 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standa...
Detailed Description
Following informed consent from patient's legally authorized representative, patients will be randomized to hydroxocobalamin or saline. Patients will have blood samples drawn up to 3 hours pre-dose an...
Eligibility Criteria
Inclusion
- Adult patients at least 18 years of age
- Admitted to the Medical Intensive Care Unit (MICU) service at Froedtert Hospital
- Diagnosis of septic shock, as defined by sepsis-3 criteria
Exclusion
- History of calcium oxaluria
Key Trial Info
Start Date :
August 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 23 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03783091
Start Date
August 5 2019
End Date
February 23 2023
Last Update
November 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226